BioWorld: The Daily Biopharmaceutical and Medical Technology …
WEBDetailed data affirm ivonescimab tops Keytruda in NSCLC trial. More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit Therapeutics and Akeso Pharmaceuticals Inc.,... Daily news and analysis of the global biotechnology, pharmaceutical and medical technology industries.
BioWorld Science: The Daily Drug R&D News Source
WEBEnjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription. Daily news focused on drug discovery, delivery and preclinical research. Coverage includes: Congress highlights, key studies from peer-reviewed journals, chemical structure images, …
Boston Scientific buying Devoro Medical for $269M ... - BioWorld
WEBSep 21, 2021 · Boston Scientific Corp. grabbed the remaining shares of Devoro Medical Inc. and its Wolf thrombectomy platform in a transaction valued at $269 million. Freemont, Calif.-based Devoro stands to gain an additional $67 million if the company achieves undisclosed clinical and regulatory milestones. Boston Scientific began investing in Devoro in 2019 …
Rhythm wins first FDA approval for obesity drug Imcivree
WEBNov 30, 2020 · Rhythm Pharmaceuticals Inc., a company developing medicines for rare genetic disorders of obesity, has won FDA approval for its first product, Imcivree (setmelanotide), following a priority review. The drug is designed to restore a biological pathway that, when disrupted, can lead to constant hunger. The approval covers the …
With series A backing, Leucid heads for clinic with third ... - BioWorld
WEBOct 21, 2021 · There’s a whole group of biotechs trying to create a tougher next-generation CAR T-cell therapy that could have a powerful effect on solid tumors after the technology’s first successes in blood cancer. One of those is London-based Leucid Bio Ltd., which has just raised £11.5 million (nearly US$16 million) in series A financing to develop next …
China’s new policy gives innovative drugs direct access to
WEBApr 20, 2021 · Now drugmakers can gain instant access to hospitals in Hainan province right after their innovative drugs are approved by China’s National Medical Products Administration (NMPA) to skip market entry hurdles. This new measure comes after Hainanese authorities allowed innovative drugs that have yet to be greenlighted in …
Gut microbial metabolites facilitate anticancer therapy
WEBMarch 30, 2021. By John Fox. A study led by Chinese scientists at Tsinghua University in Beijing has demonstrated that the gut microbial metabolite butyrate can directly modulate the antitumor CD8 "killer" T-cell response and improve chemotherapy efficacy through ID2-dependent IL-12 signaling. Reported in the March 23, 2021, online edition of ...
Organoids making their US clinical debut with CIDP drug
WEBJul 15, 2022 · Organoids making their US clinical debut with CIDP drug. July 15, 2022. By Nuala Moran. The use of organoids in preclinical research has reached a tipping point, with U.S. FDA approval of the first drug to enter clinical trials on the basis of efficacy data derived only from these advanced cell models. BioWorld BioWorld MedTech Regulatory …
Nuvation to buy Anheart, cancer pipeline in all-stock deal
WEBMar 26, 2024 · Nuvation Bio Inc. said on March 25 it will acquire Anheart Therapeutics Ltd., a U.S.- and China-based precision oncology company, in an all-stock transaction, adding Anheart’s ROS1-inhibiting lung cancer drug, taletrectinib (AB-106), to its pipeline. Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of ...
Amyloid Solution patents new MAPT and Aβ aggregation
WEBJan 24, 2024 · Amyloid Solution patents new MAPT and Aβ aggregation inhibitors for Alzheimer’s disease. Jan. 24, 2024. Amyloid Solution Inc. has disclosed microtubule-associated protein tau (PHF-tau; MAPT) and/or... BioWorld Science Neurology/psychiatric Patents. Cumulus raising $50M, spinning GPR68 small molecules into GIO.